Literature DB >> 3974452

Increased dopamine production in patients with carcinoid tumors.

J M Feldman.   

Abstract

Although both carcinoid tumors and pheochromocytomas arise from neural crest origin, they are thought to each secrete distinctive monoamines; carcinoid tumors, which contain tryptophan hydroxylase, secrete serotonin, and pheochromocytomas, which contain tyrosine hydroxylase, may secrete dopamine (DA), norepinephrine (NE), or epinephrine (E). The purpose of this study was to determine if patients with carcinoid tumors have evidence of increased DA production. Of patients with serotonin-producing carcinoid tumors, 18%, 27%, and 35%, respectively, had increased urinary homovanillic acid (HVA) excretion (the principal metabolite of DA), urinary DA excretion, and plasma DA concentration. In contrast, none of the patients with nonserotonin-producing carcinoid tumors had evidence of increased DA production. Only 4% of patients with miscellaneous tumors had increased excretion of homovanillic acid or DA; none of the patients with miscellaneous tumors had increased plasma DA concentration. This study suggests that DA and HVA measurements may be useful in the evaluation of some patients with suspected carcinoid tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974452     DOI: 10.1016/0026-0495(85)90009-5

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  5 in total

1.  Detecting pheochromocytoma: defining the most sensitive test.

Authors:  Ulrich Guller; Joe Turek; Steve Eubanks; Elizabeth R Delong; Daniel Oertli; Jerome M Feldman
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

Review 2.  The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid.

Authors:  W P Tormey; R J FitzGerald
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

3.  Use of somatostatin analog in management of carcinoid syndrome.

Authors:  A Vinik; A R Moattari
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

4.  Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Aejaz Nasir; Pamela Hodul; Larry Kvols
Journal:  Gastrointest Cancer Res       Date:  2008-05

5.  Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour.

Authors:  Helle-Brit Fiebrich; Johan R de Jong; Ido P Kema; Klaas Pieter Koopmans; Wim Sluiter; Rudi A J O Dierckx; Annemiek M Walenkamp; Thera P Links; Adrienne H Brouwers; Elisabeth G E de Vries
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-06-23       Impact factor: 9.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.